Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2004

View Archived Issues

Perlegen and Pfizer to analyze drug response in patients with major depression

Cypress Bioscience, Forest and Pierre Fabre announce agreement for milnacipran

HemispheRx and Vanderbilt University announce joint SARS clinical program

Metabasis Therapeutics announces collaboration to develop treatments for hepatitis C

Purdue Pharma files petition with FDA for generic forms of OxyContin

Gefitinib shows promise in the treatment of recurrent glioblastoma

Protective effects against UV irradiation reported for topical lycopene

Cell type-specific metabolism of testosterone in human skin

Acumen and Merck team to develop drugs for Alzheimer's disease

AnorMED expands Fosrenol licensing agreement

Boehringer Ingeheim claims new glucocorticoid receptor modulators and their use

Novel NHE-1 inhibitors in early development at Aventis

New HCV NS5B inhibitors identified at NeoGenesis

Chinese researchers design dual 5-HT/NA reuptake inhibitors for use as antidepressants

MediGene names Yamanouchi as pan-European partner for prostate cancer products

Corixa and GSK Bio to commence phase I study of tuberculosis vaccine

Aventis claims new NHE-3 inhibitors for sleep apnea and other disorders

Genzyme presents new kallikrein/urokinase inhibitors for pain, inflammation and cancer

Studies support antiinflammatory and antiatherosclerotic effects of PPARgamma agonist

AVE-7688 reduces nephropathy in type 2 diabetes

Pharmacological profile of 5-HT2C agonist YM-348

Development of an improved orally active 5-lipoxygenase inhibitor

Novel mixed opioid analgesic with limited effects on respiratory function

Roche submits European MAA for MabThera

Eloxatin submitted for adjuvant treatment of colon cancer in U.S. and Europe

New phase II trial of Trovax in colorectal cancer cleared to begin in U.K.

Taxotere approved in Japan for esophageal cancer

HER-2 Protein AutoVac induces antibody responses in breast cancer trial

First world launch of Pfizer's antifungal agent fosfluconazole in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...